Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Status:
RECRUITING
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.